Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Pilot Study of the IGF-1R Inhibitor AXL1717 in Combination With Gemcitabine HCL and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Squamous Non-small-cell Lung Cancer

NCT01466647 is registered in ClinicalTrials.gov with Axelar AB as lead sponsor.

NCT NCT01466647
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01466647 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Pilot Study of the IGF-1R Inhibitor AXL1717 in Combination With Gemcitabine HCL and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Squamous Non-small-cell Lung Cancer
Lead sponsor
Axelar AB
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2011
Completion date
September 30, 2012
Enrollment
12 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer